Friday, October 7, 2016

Renografin-60





Dosage Form: Injection


NOT FOR INTRATHECAL USE




Renografin-60 Description


Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Each mL provides 520 mg diatrizoate meglumine and 80 mg diatrizoate sodium; at manufacture, 3.2 mg sodium citrate and 0.4 mg edetate disodium are added per mL. The pH has been adjusted between 6.0 and 7.7 with sodium hydroxide and diatrizoic acid. Each mL of solution also contains approximately 3.76 mg (0.16 mEq) sodium and 292.5 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen.



Renografin-60 - Clinical Pharmacology


Following intravascular injection, Renografin-60 is rapidly transported through the bloodstream to the kidneys and is excreted unchanged in the urine by glomerular filtration. When urinary tract obstruction is severe enough to block glomerular filtration, the agent appears to be excreted by the tubular epithelium.


Certain applications of the contrast agent make use of the natural physiologic mechanism of excretion. Thus, the intravenous injection of the agent permits visualization of the kidneys and urinary passages.


Renal accumulation is sufficiently rapid that the period of maximal opacification of the renal passages may begin as early as five minutes after injection. In infants and small children excretion takes place somewhat more promptly than in adults, so that maximal opacification occurs more rapidly and is less sustained. The normal kidney eliminates the contrast medium almost immediately. In nephropathic conditions, particularly when excretory capacity has been altered, the rate of excretion varies unpredictably, and opacification may be delayed for 30 minutes or more after injection; with severe impairment opacification may not occur. Generally, however, the medium is concentrated in sufficient amounts and promptly enough to permit a thorough evaluation of the anatomy and physiology of the urinary tract. After intramuscular injection, the contrast agent is promptly absorbed and normally reaches the renal passages within 20 to 60 minutes.


Intravascular injection of diatrizoate also opacifies those vessels in the path of flow of the medium, permitting visualization until the circulating blood dilutes the concentration of the medium. Thus selective angiography may be performed following injection directly into veins or arteries such as the carotid, the vertebral, or the vessels of the extremities.


Under certain circumstances, specific parts of the body which do not concentrate the contrast agent physiologically may be visualized by injecting the agent directly into the region to be studied. The biliary tract is one organ system which may be visualized in this manner. In operative cholangiography, injection of the radiopaque medium into the cystic duct or choledochal lumen, at laparotomy, opacifies the intra- and extra-hepatic biliary ductal system, revealing the nature and location of obstructions such as stones or strictures. Injection of the medium through an in-place T-tube, immediately after exploration of the common duct, permits the visualization of retained stones. A repetition of “T-tube cholangiography,” performed as part of the postoperative follow-up, insures the patency of the ductal system before removal of the T-tube. The biliary ductal system may also be opacified by the percutaneous transhepatic route. In relatively long-standing biliary obstruction, the biliary ducts are usually enlarged sufficiently to be located promptly by percutaneous transhepatic probing, permitting injection of the contrast agent directly into the biliary ductal system.


If the contrast agent is injected directly into the splenic pulp, significant opacification of the splenic and portal veins is obtained. Because of gravity, the dependent portions of the portal system are better opacified than the superior portions. The agent is carried from the portal vein into the hepatic veins, and a diffuse opacification of the liver results. In patients with portal hypertension, collateral pathways caused by the change in portal blood flow may be visualized and esophageal varices are often delineated. The procedure may reveal the site of portal obstruction.


Injection of Renografin-60 directly into a joint space provides visual information about joint derangements.


A small amount of the radiopaque agent injected into a normal cervical or lumbar disk will, under optimal conditions, concentrate within the nucleus pulposus. In the presence of disk pathology the injected agent may reveal significant bulging or disruption of the annulus beyond its normal confines and may identify disk degeneration, retropulsion, or rupture.



Computed Tomography


Renografin-60 enhances computed tomographic brain scanning through augmentation of radiographic efficiency. The degree of enhancement of visualization of tissue density is directly related to the iodine content in an administered dose; peak iodine blood levels occur immediately following rapid injection of the dose. These levels fall rapidly within five to ten minutes.This can be accounted for by the dilution in the vascular and extracellular fluid compartments which causes an initial sharp fall in plasma concentration. Equilibration with the extracellular compartments is reached in about ten minutes; thereafter, the fall becomes exponential. Maximum contrast enhancement frequently occurs after peak blood iodine levels are reached. The delay in maximum contrast enhancement can range from five to forty minutes, depending on the peak iodine levels achieved and the cell type of the lesion. This lag suggests that radiographic contrast enhancement is at least in part dependent on the accumulation of iodine within the lesion and outside the blood pool, although the mechanism by which this occurs is not clear. The radiographic enhancement of nontumoral lesions, such as arteriovenous malformations and aneurysms is probably dependent on the iodine content of the circulating blood pool.


In brain scanning, Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) does not accumulate in normal brain tissue due to the presence of the “blood-brain” barrier. The increase in X-ray absorption in normal brain is due to the presence of contrast agent within the blood pool. A break in the blood-brain barrier such as occurs in malignant tumors of the brain allows the accumulation of the contrast medium within the interstitial tumor tissue. Adjacent normal brain tissue does not contain the contrast medium.


In nonneural tissues (during computed tomography of the body), diatrizoate diffuses rapidly from the vascular into the extravascular space. Increase in X-ray absorption is related to blood flow, concentration of the contrast medium, and extraction of the contrast medium by interstitial tumor tissue since no barrier exists. Contrast enhancement is thus due to the relative differences in extravascular diffusion between normal and abnormal tissue, quite different from that in the brain.


The pharmacokinetics of diatrizoate in both normal and abnormal tissue have been shown to be variable. Contrast enhancement appears to be greatest soon after administration of the contrast medium, and following intra-arterial rather than intravenous administration. Thus, greatest enhancement can be detected by a series of consecutive two- to three-second scans performed just after injection (within 30 to 90 seconds), i.e., dynamic computed tomographic scanning.



INDICATIONS


Renografin-60 is indicated in excretion urography (by direct I.V. or drip infusion); cerebral angiography; peripheral arteriography; venography; operative, T-tube, or percutaneous transhepatic cholangiography; splenoportography; arthrography; and discography.



Computed Tomography


Renografin-60 is also indicated for radiographic contrast enhancement in computed tomography (CT) of the brain and body. Contrast enhancement may be advantageous in delineating or ruling out disease in suspicious areas which may otherwise not have been satisfactorily visualized.


Brain Tumors

Renografin-60 may be useful to demonstrate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas; ependymomas; medulloblastomas; meningiomas; neuromas; pinealomas; pituitary adenomas; craniopharyngiomas; germinomas; and metastatic lesions.


The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In cases where lesions have calcified, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement.


Non-Neoplastic Conditions of The Brain

The use of Renografin-60 may be beneficial in the enhancement of images of lesions not due to neoplasms. Cerebral infarctions of recent onset may be better visualized with the contrast enhancement, while some infarctions are obscured if a contrast medium is used. The use of Renografin-60 improved the contrast enhancement in approximately 60 percent of cerebral infarctions studied from one week to four weeks from the onset of symptoms.


Sites of active infection also will produce contrast enhancement following contrast medium administration.


Arteriovenous malformations and aneurysms will show contrast enhancement. In the case of these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool.


Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast medium administration may be helpful in ruling out the possibility of associated arteriovenous malformation.


The opacification of the inferior vermis following contrast medium administration has resulted in false-positive diagnoses in a number of normal studies.


Body Scanning

Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) maybe used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space.


Enhancement of computed tomography with Renografin-60 may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g., tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst).


Contrast enhancement appears to be greatest within 60-90 seconds after bolus administration of the contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the non-perfused mass shows unchanged X-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion.


Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings.



Contraindications


Renografin-60 is contraindicated for use in intrathecal procedures. This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.


Urography is contraindicated in patients with anuria.


Specific contraindications to percutaneous transhepatic cholangiography include a prothrombin time below 50 percent and evidence of coagulation defects.


Splenoportography should not be performed on any patient for whom splenectomy is contraindicated, since complications of the procedure at times make splenectomy necessary. Other contraindications include prothrombin time below 50 percent, significant thrombocytopenia or coagulation defect, and any condition which may increase the possibility of rupture of the spleen.


Arthrography should not be performed if infection is present in or near the joint.


Discography should not be performed in patients with an infection or open injury near the region to be examined.



Warnings



Severe Adverse Events — Inadvertent Intrathecal Administration


Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to insure that this drug product is not inadvertently administered intrathecally.


The possibility exists for inadvertent administration into the intrathecal space during epidural administrations. Therefore, epidural administration procedures, such as pain management catheter placement, should not be performed with use of this product.



General


Ionic iodinated contrast media inhibit blood coagulation, in vitro, more than nonionic contrast media. Nonetheless, it is prudent to avoid prolonged contact of blood with syringes containing ionic contrast media.


Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events. Numerous factors, including length of procedure, catheter and syringe material, underlying disease state, and concomitant medications may contribute to the development of thromboembolic events. For these reasons, meticulous angiographic techniques are recommended including close attention to guidewire and catheter manipulation, use of manifold systems and/or three way stopcocks, frequent catheter flushing with heparinized saline solutions, and minimizing the length of the procedure. The use of plastic syringes in place of glass syringes has been reported to decrease but not eliminate the likelihood of in vitro clotting.


A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma. In such instances there has been anuria resulting in progressive uremia, renal failure, and eventually death. Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be the causative factor. The risk in myelomatous patients is not a contraindication to the procedures; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to the precipitation of myeloma protein in the renal tubules. No form of therapy, including dialysis, has been successful in reversing this effect. Myeloma, which occurs most commonly in persons over age 40, should be considered before intravascular administration of a contrast agent.


Administration of radiopaque materials to patients known or suspected to have pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risks, the procedures may be performed; however, the amount of radiopaque medium injected should be kept to an absolute minimum. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.


Contrast media have been shown to promote the phenomenon of sickling in individuals who are homozygous for sickle cell disease when the material is injected intravenously or intra-arterially.


Since iodine-containing contrast agents may alter the results of thyroid function tests, such tests, if indicated, should be performed prior to the administration of this preparation.


A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate but calls for extreme caution in administration.


Avoid accidental introduction of this preparation into the subarachnoid space since even small amounts may produce convulsions and possible fatal reactions. In patients with subarachnoid hemorrhage, a rare association between contrast administration and clinical deterioration, including convulsions and death, has been reported; therefore, administration of intravascular iodinated ionic contrast media in these patients should be undertaken with caution.


Cerebral angiography should be undertaken with special caution in extreme age, poor clinical condition, advanced arteriosclerosis, severe arterial hypertension, cardiac decompensation, recent cerebral embolism, or thrombosis.


Urography should be performed with extreme caution in patients with severe concomitant hepatic and renal disease.



Precautions


Diagnostic procedures which involve the use of radiopaque diagnostic contrast agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for coping with any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself. After parenteral administration of a radiopaque agent, competent personnel and emergency facilities should be available for at least 30 to 60 minutes since severe delayed reactions have occured (see ADVERSE REACTIONS).


Severe, life-threatening reactions suggest hypersensitivity to the radiopaque agent, which has prompted the use of several pretesting methods, none of which can be relied upon to predict severe reactions. Many authorities question the value of any pretest. A history of bronchial asthma or allergy, a family history of allergy, or a previous reaction to a contrast agent warrant special attention. Such a history, by suggesting histamine sensitivity and a consequent proneness to reactions, may be more accurate than pretesting in predicting the likelihood of a reaction, although not necessarily the severity or type of reaction in the individual case.


The sensitivity test most often performed is the slow injection of 0.5 to 1.0 mL of the radiopaque medium, administered intravenously, prior to injection of the full diagnostic dose. It should be noted that the absence of a reaction to the test dose does not preclude the possibility of a reaction to the full diagnostic dose. If the test dose causes an untoward response of any kind, the necessity for continuing with the examination should be carefully reevaluated and, if it is deemed essential, the examination should be conducted with all possible caution. In rare instances, reactions to the test dose itself may be extremely severe; therefore, close observation of the patient, and facilities for emergency treatment, appear indicated.


Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by urographic agents. Administration of Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) should therefore be postponed in any patient with a known or suspected hepatic or biliary disorder who has recently taken a cholecystographic contrast agent.


Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension. The possibility of thrombosis should be borne in mind when percutaneous techniques are employed.


Consideration must be given to the functional ability of the kidneys before injecting this preparation.


Contrast agents may interfere with some chemical determinations made on urine specimens therefore, urine should be collected before administration of the contrast medium or two or more days afterwards.


The following precautions pertain to specific procedures:


Peripheral arteriography: Hypotension or moderate decreases in blood pressure seem to occur frequently with intra-arterial (brachial) injections; therefore, the blood pressure should be monitored during the immediate ten minutes after injection; this blood pressure change is transient and usually requires no treatment.


Excretion urography: Adequate visualization may be difficult or impossible to attain in uremic patients or others with severely impaired renal function (see CONTRAINDICATIONS). The increased osmotic load associated with drip infusion pyelography should be considered in patients with congestive heart failure. The diuretic effect of the drip infusion pyelography procedure may hinder assessment of residual urine in the bladder. The recommended rate of infusion should not be exceeded.


Acute renal failure has been reported in diabetic patients with diabetic nephropathy and susceptible nondiabetic patients (often elderly with preexisting renal disease) following excretion urography, Therefore, careful consideration should be given before performing this procedure in these patients.


Operative and T-tube cholangiography: Injection should be made slowly to prevent extravasation of the medium into the peritoneal cavity, and to minimize reflux flow into the pancreatic duct which may result in pancreatic irritation.


Percutaneous transhepatic cholangiography: To reduce the possibility of bile leakage and consequent peritonitis, as much of the contrast agent as possible should be aspirated on completion of successful films. All patients should be carefully and constantly monitored for 24 hours after the procedure for signs of internal hemorrhage or bile leakage; if these complications are recognized immediately, remedial measures can be instituted promptly with minimal increase in morbidity. Percutaneous transhepatic cholangiography is not without risk and should therefore be reserved for special circumstances when ordinary studies of the biliary system have failed to provide the requisite information in jaundiced patients who are not good candidates for surgery. The procedure should only be attempted when competent surgical intervention can be promptly obtained if needed.


Splenoportography: It is best to avoid manipulations which would prolong the time the needle is in the spleen, since they may contribute to subcapsular extravasation of the contrast agent, and also to postpuncture bleeding. Following splenoportography, the patient should lie on his left side for several hours and should be closely observed for 24 hours for signs of internal bleeding, which is the most common complication of the procedure. Fatal hemorrhage has occurred on rare occasion, but leakage of up to 300 mL of blood from the spleen is apparently not uncommon. Blood transfusions may be required, and rarely splenectomy.


Discography: To minimize the possibility of introducing infection, discography should be postponed in any patient with an infection or open injury near the region to be examined, including upper respiratory infections in the case of cervical discography. All possible care should be taken to preclude contamination and resultant infection of the disk, which has been reported after discography. In cervical discography, particular care is needed to avoid puncturing the esophagus and thereby introducing contamination into the disk. Rupture of the disk is highly unlikely if care in performance is observed, but may occur if the point of the needle has been barbed by contact with bone; use of the two-needle technique should help reduce this hazard.



USAGE IN PREGNANCY


Safety for use during pregnancy has not been established; therefore, this preparation should be used in pregnant patients only when, in the judgment of the physician, its use is deemed essential to the welfare of the patient.



Adverse Reactions


Mild, moderate, and sometimes severe adverse reactions may occur associated with the procedure and/or the contrast media. Reactions known to occur with parenteral administration of iodinated ionic contrast media (see the listing below) are possible with a nonionic agent. Approximately 95 percent of adverse reactions accompanying the use of other water-soluble intravascularly administered contrast agents are mild to moderate in degree. However, severe and life-threatening reactions and fatalities, mostly of cardiovascular origin, have occurred.


Reported incidences of death from the administration of other iodinated contrast media range from 6.6 per 1 million (0.00066 percent) to 1 in 10,000 patients (0.01 percent). Most deaths occur during injection or 5 to 10 minutes later, the main feature being cardiac arrest with cardiovascular disease as the main aggravating factor. Isolated reports of hypotensive collapse and shock are found in the literature. The incidence of shock is estimated to be 1 out of 20,000 (0.005 percent) patients.


Nausea, vomiting, flushing, or a generalized feeling of warmth are the reactions seen most frequently with intravascular injection. Symptoms which may occur are chills, fever, sweating, headache, dizziness, pallor, weakness, severe retching and choking, wheezing, a rise or fall in blood pressure, facial or conjunctival petechiae, urticaria, pruritus, rash, and other eruptions, edema, cramps, tremors, itching, sneezing, lacrimation, etc. Antihistaminic agents may be of benefit; rarely such reactions may be severe enough to require discontinuation of dosage.


Severe reactions which may require emergency measures may take the form of a cardiovascular reaction characterized by peripheral vasodilatation with resultant hypotension and reflex tachycardia, dyspnea, agitation, confusion and cyanosis progressing to unconsciousness. Or, the histamine-liberating effect of these compounds may induce an allergic-like reaction which may range in severity from rhinitis or angioneurotic edema to laryngeal or bronchial spasm or anaphylactoid shock.


Temporary renal shutdown or other nephropathy may occur. Temporary neurologic effects of varying severity have occurred in a few instances, particularly when the medium was used for angiography in the diagnosis of cerebral pathology. Although local tissue tolerance is usually good, there have been a few reports of a burning or stinging sensation or numbness and of venospasm or venous pain, and partial collapse of the injected vein. Neutropenia or thrombophlebitis may occur.


Adverse effects may sometimes occur as a consequence of the procedure for which the contrast agent is used. Adverse reactions inexcretion urography have included cardiac arrest, ventricular fibrillation, anaphylaxis with severe asthmatic reaction, and flushing due to generalized vasodilation. Cerebral angiography has been known to cause temporary neurologic complications such as induction of seizures, particularly in patients with convulsive disorders; confusional states or drowsiness; transient paresis; coma; temporary disturbances in vision; or seventh nerve weakness. During peripheral arteriography, complications have occurred including hemorrhage from the puncture site, thrombosis of the vessel, and brachial plexus palsy following axillary artery injections.


Complications of percutaneous transhepatic cholangiography have been estimated to occur in four to six percent of cases and have included bile leakage and biliary peritonitis, gall-bladder perforation, internal bleeding, septicemia involving gram-negative organisms, and tension pneumothorax from inadvertent puncture of the diaphragm and lung. Bile leakage may be more likely in patients with complete obstruction due to carcinoma.


During splenoportography, intraperitoneal extravasation of the contrast medium may cause transient diaphragmatic irritation or mild to moderate transient pain which may sometimes be referred to the shoulder, the periumbilical region, or other areas. Because of the proximity of the pleural cavity, accidental pneumothorax has been known to occur. Inadvertent injection of the medium into other nearby structures is not likely to cause untoward consequences.


Arthrography may induce joint pain or increase existing pain, particularly if a large dose is used and the medium extravasates into surrounding soft tissue. Pain or discomfort is usually immediate and transient but may be delayed or of extended duration (up to 24 hours). Lipid-filled histiocytes have been found in tissue removed following arthrography. The technique of discography may be painful, particularly when disk pathology exists. Pain on injection may also be related to the volume of the dose. The nature of the disk pathology or extravasation of contrast agent may cause referred pain.


When any percutaneous technique is employed the possibility of thrombosis or of other complications due to the mechanical trauma of the procedure should be borne in mind.



Renografin-60 Dosage and Administration


Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) should be at body temperature when injected, and may need to be warmed before use. If kept in a syringe for prolonged periods before injection, it should be protected from exposure to strong light.


Dilution and withdrawal of the contrast agent should be accomplished under aseptic conditions with sterile needle and syringe.



Excretion Urography


Appropriate preparation of the patient is desirable for optimal results. In adults and older children, a laxative the night before the examination, a low residue diet the day before, and low liquid intake for 12 hours prior to the procedure may be used to clear the gastrointestinal tract and to induce a partial dehydration which is believed to increase the urinary concentration of the contrast medium. Preparatory partial dehydration is not recommended in infants, young children, the elderly, or azotemic patients (especially those with polyuria, oliguria, diabetes, advanced vascular disease, or preexisting dehydration). The undesirable dehydration in these patients may be accentuated by the osmotic diuretic action of the medium.


In uremic patients partial dehydration is not necessary and maintenance of adequate fluid intake is particularly desirable.



Direct I.V. Injection: The dose range for adults is 25 to 50 mL; the usual dose is 25 mL; children require proportionately less. Suggested dosages are as follows: Under 6 months-5 mL; 6 to 12 months-8 mL; 1 to 2 years-10 mL; 2 to 5 years-12 mL; 5 to 7 years-15 mL; 8 to 10 years-18 mL; 11 to 15 years-20 mL; adults (16 years and older)-25 to 50 mL. In adults, when the smaller dose has provided inadequate visualization, or when poor visualization is anticipated, the 50 mL dose may be given. Drip infusion may be used when direct I.V. pyelography is not expected to be or has not been satisfactory (see below).


The preparation is given by intravenous injection. If flushing or nausea occurs during administration, injection should be slowed or briefly interrupted until the side effects have disappeared.


A scout film should be made before the contrast medium is administered. To allow for individual variation, several films should be exposed beginning approximately five minutes after injection. In patients with renal dysfunction optimal visualization may be delayed until 30 minutes or more after injection.


NOTE: In infants and children and in certain adults the medium may be injected intramuscularly. The suggested dose is 25 mL for adults and proportionately less for children, divided and given bilaterally in the gluteal muscles. Radiographs should be taken at 20, 40, and 60 minutes after the medium is injected.



Drip Infusion Pyelography: In drip infusion pyelography, the recommended dose of Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) is calculated on the basis of 1 mL of Renografin-60 per pound of body weight diluted with an equal volume of Sterile Water for Injection USP. The diluted preparation (30%) is given by I.V. infusion through a large bore (17- to 18-gauge) needle at a rate of 40 mL per minute. The recommended rate of infusion should not be exceeded and the total volume administered should generally not exceed 300 mL. In older patients and in patients with known or suspected cardiac decompensation, a slower rate of infusion is probably wise.


If nausea or flushing occurs during administration, the infusion should be slowed or briefly interrupted.


Films are taken before the onset of the infusion and at the desired intervals following its completion. When renal function is normal, a nephrogram may be taken as soon as the infusion is completed, and films of the collecting system at 10 and 20 minutes thereafter. Voiding cystourethrograms are usually optimal at 20 minutes after the infusion is completed. In hypertensive patients, early minute sequence films may be taken during the course of infusion, in addition to subsequent pyelograms. In patients with renal dysfunction, optimal visualization is usually delayed, and late films are taken as indicated.


The nephrogram obtained by the drip infusion procedure may be dense enough to obscure the pelvocalyceal system in some cases. The presence of gas in the bowel may hamper early visualization of the renal collecting system. Tomographic “cuts” may help to overcome such difficulties.


Nephrotomography may begin when the infusion is completed. The sustained contrast achieved by the drip infusion technique eliminates the need for precise timing and teamwork that is necessary with ordinary nephrotomography. Thus, if nephrograms taken after infusion of the medium suggest the need for sectional films, or if preselected tomographic “cuts” are not sufficient, additional tomograms may be obtained at once, and without repetition of dosage.



Cerebral Angiography


Appropriate preparation of the patient is indicated, including suitable premedication. The average single dose for adults is 10 mL, repeated as indicated. Children require less in proportion to weight.


Either the percutaneous or operative method of administration may be used. For visualization of the cerebral vessels, the contrast medium is injected into the common carotid artery; for angiography of the vessels in the posterior fossa or the occipital lobes, the medium is injected into the vertebral artery. Since the medium is given by rapid injection, the patient should be watched for untoward reactions. Unless general anesthesia is used, patients should be warned that the medium may provoke movement and that they may feel transient pain, flushing, or burning during the injection.


A scout film should be made routinely before the contrast medium is injected. Serial films begun while the last few mL are being injected should permit visualization of the arterial, intermediate, and venous phases.



Peripheral Arteriography


Appropriate preparation of the patient is indicated, including suitable premedication. For visualization of an entire extremity, a single dose of 20 to 40 mL is suggested; for the upper or lower half of the extremity only, 10 to 20 mL is usually sufficient.


Injection is made into the femoral or subclavian artery by the percutaneous or operative method. Because the contrast agent is given by rapid injection, flushing of the skin may occur. Patients not under general anesthesia may experience nausea and vomiting or a transient feeling of warmth. Vascular spasm is not likely to occur.


A scout film should be made routinely before administering the contrast medium. Radiograms of the upper half of the extremity are taken while the last few mL are being injected, followed by radiograms of the lower half of the extremity a few seconds later.



Venography


For visualization of veins in the upper extremities, a single dose of 10 mL per extremity is suggested. For veins in the lower extremities, doses of 20 to 40 mL per extremity are suggested. In exceptional circumstances, larger doses may be necessary; visualization of the iliac vein, extensive varicosities or large veins may require 50 mL or more. Total doses up to 100 mL per lower extremity have been used safely.


For visualization of an upper extremity, the medium may be given by percutaneous injection into any convenient superficial vein of the forearm or hand. For the visualization of a lower extremity it should be injected into a superficial vein on the lateral side of the foot. The medium is injected rapidly; patients should be observed for untoward reactions.


Radiograms are taken when injection is completed; sufficient time should be allowed to permit diffusion of the contrast medium.



Operative and Postoperative Cholangiography


Operative cholangiography is performed as soon as the gallbladder and ducts have been exposed surgically. The usual dose is 10 mL but as much as 25 mL may be needed, depending on the caliber of the ducts. If desired, the contrast agent may be diluted 1:1 with Sodium Chloride Injection USP under strict aseptic procedures.


The contrast medium is instilled slowly through the stump of the cystic duct or directly into the choledochal lumen. Following surgical exploration of the ductal system, repeat studies may be performed before closure of the abdomen, using the same dose as before.


Postoperatively, the ductal system may be examined by injection of the contrast agent through an in-place T-tube. “T-tube cholangiography” is usually performed eight to ten days after operation; the usual dose is the same as for operative cholangiography.


For each procedure, films are taken immediately after instillation of the medium and are read immediately. Additional films are then taken if necessary.



Percutaneous Transhepatic Cholangiography


Facilities for emergency surgery should be available whenever this examination is performed. Appropriate premedication of the patient is recommended; drugs which are likely to cause spasm, such as morphine, should be avoided.


Depending on the caliber of the biliary tree, a dose of 20 to 40 mL is generally sufficient to opacify the entire ductal system. The contrast agent may be diluted 1:1 with Sodium Chloride Injection USP, if desired, under strict aseptic procedures.


Injection is made into a biliary duct by the percutaneous transhepatic method. Before the dose is administered, as much bile as possible is aspirated. The medium is then slowly injected into the duct under very slight pressure. If a duct is not located promptly, successive small doses of 1 to 2 mL are injected into the liver as the needle is gradually withdrawn, until a duct is visualized by x-ray. If no duct can be located after three or four attempts, the procedure is abandoned.


Serial films are taken rapidly during and after injection of the medium into the biliary ducts. Repositioning of the patient, if necessary, should be done with care.


In hepatocellular disease, the biliary ducts are generally not enlarged and cannot successfully be opacified by this method. Thus, in the presence of long-standing jaundice, failure to obtain a successful percutaneous transhepatic cholangiogram by a person experienced in the technique is generally considered to be strongly suggestive of nonobstructive or hepatocellular-type jaundice.



Splenoportography


Prior gastrointestinal x-ray examination should include particular attention to the lower esophageal area. A hematologic survey, including prothrombin time and platelet count, should be performed. The patient should have no food for several hours and should be mildly sedated. Splenoportography is usually performed under local anesthesia.


Approximately 20 to 25 mL of the contrast agent is usually adequate. The dose is injected rapidly, following radiologic location and percutaneous puncture of the spleen.


Preliminary films are taken to locate the spleen before the injection is begun. Rapid serial films are then started simultaneously with injection of the dose. Serial films are necessary since the entire portal system cannot be captured on a single film and also because of individual variations in portal circulation time.



Arthrography


The amount of contrast agent required is dependent on the size of the joint to be injected. For an adult, the following doses are generally suitable: knee-5 to 15 mL; shoulder or hip-5 to 10 mL; other joints-1 to 4 mL. Dosage for children should be suitably reduced.


The injection site should be prepared aseptically. Excessive synovial fluid should be aspirated to minimize pain and to reduce intra-articular dilution of the contrast agent. If indicated, the agent may be administered under local anesthesia. After injection of the medium, the joint should be manipulated gently in order to spread the medium throughout the joint space. In some instances, double contrast arthrography, injecting both air and contrast medium, has been of value.


Films are taken from several angles; stereoscopic films may be advantageous.


When the contrast agent is used to opacify a joint space, much of the agent may be aspirated at the end of the procedure.



Discography


No prior preparation of the patient is required, although administration of an analgesic or sedative 20 minutes before the procedure may be helpful. Discography is performed under local anesthesia using the usual aseptic precautions.


Dosage is generally determined by the amount of contrast agent which can easily be injected into the disk without force. A cervical disk will normally accept up to 0.5 mL and a lumbar disk 1 or 2 mL. The amount may vary, and injection should be discontinued when resistance is felt. The rate of injection may influence the amount which can be injected. To reduce the probability of extravasation and to minimize unnecessary pain, injection should be made slowly and not more than 2 mL should be injected into any one disk.


A two-needle technique may be used to administer the contrast medium, with a large-gauge needle to locate the disk and a small-gauge needle within the larger one to puncture the disk and administer the medium. The correct position of the two needles is established radiologically before the medium is injected.


Spot roentgenograms should be taken anteroposteriorly, obliquely, and laterally as soon as disks have been injected.


When the contrast agent is used for discography, it need not be aspirated at the end of the procedure.



Computed Tomography


Brain Scanning

The suggested dose range is 50 to 150 mL by intravenous administration; scanning may be performed immediately after completion of administration. Doses for children should be proportionately less, depending on age and weight.


Body Scanning

The usual adult dose is 100 mL administered by rapid intravenous (within approximately 1 minute) bolus injection. Scanning is performed immediately after injection.


Gastrografin® (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP), an oral radiopaque contrast agent, may be useful as an adjunct to the procedure.


Patient Preparation

No special patient preparation is required for contrast enhancement of CT brain scanning or body scanning. However, it is advisable to insure that patients are well hydrated prior to examination.



How is Renografin-60 Supplied


Renografin-60 (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) is available in packages of:

Ten 50 mL single dose vials (NDC 0270-0707-49)

Ten 100 mL single dose bottles (NDC 0270-0707-55).



STORAGE


The preparation should be stored at 20-25°C (68-77°F) [See USP], protected from light. If precipitation or solidification has occurred due to storage in the cold, immerse the container in hot water and shake intermittently to redissolve any solids.



Manufactured for

Bracco Diagnostics Inc.

Princeton, NJ 08543

by Patheon Italia S.p.A.

03013 Ferentino (Italy)


Revised July 2006

255105







Renografin-60 
diatrizoate meglumine and diatrizoate sodium  injection, solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0270-0707
Route of AdministrationINTRAVENOUSDEA Schedule    

















INGREDIENTS
Name (Active Moiety)TypeStrength
diatrizoate meglumine (diatrizoic acid)Active520 MILLIGRAM  In 1 MILLILITER
diatrizoate sodium (diatrizoic acid)Active80 MILLIGRAM  In 1 MILLILITER
edetate disodiumInactive0.4 MILLIGRAM  In 1 MILLILITER
sodium citrateInactive3.2 MILLIGRAM  In 1 MILLILITER


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      

Remedy Skin Repair Cream


Pronunciation: dye-METH-i-kone
Generic Name: Dimethicone
Brand Name: Examples include Aveeno Moisturizing Lotion and Johnson's Baby Cream


Remedy Skin Repair Cream is used for:

Treating or preventing dry, itchy skin or minor skin irritations.


This product is an emollient. It works by moisturizing the skin.


Do NOT use Remedy Skin Repair Cream if:


  • you are allergic to any ingredient in Remedy Skin Repair Cream

Contact your doctor or health care provider right away if any of these apply to you.



Before using Remedy Skin Repair Cream:


Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have an open wound, serious burn, or damaged, broken, or irritated skin

Some MEDICINES MAY INTERACT with Remedy Skin Repair Cream. However, no specific interactions with Remedy Skin Repair Cream are known at this time.


Ask your health care provider if Remedy Skin Repair Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Remedy Skin Repair Cream:


Use Remedy Skin Repair Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Remedy Skin Repair Cream is for external use only. Do not get Remedy Skin Repair Cream in your eyes, nose, or mouth. If you get Remedy Skin Repair Cream in your eyes, rinse immediately with cool tap water.

  • Wash your hands before and after using Remedy Skin Repair Cream unless your hands are a part of the treated area.

  • Wash and completely dry the affected area. Apply only enough of Remedy Skin Repair Cream to completely cover the affected area and gently rub in until it is evenly distributed.

  • Do not wrap or bandage the treated area unless directed to do so by your doctor.

  • If you miss using Remedy Skin Repair Cream for 1 or more days, there is no cause for concern. If your doctor recommended that you use it, try to remember every day.

Ask your health care provider any questions you may have about how to use Remedy Skin Repair Cream.



Important safety information:


  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Remedy Skin Repair Cream while you are pregnant. If you are or will be breast-feeding while you use Remedy Skin Repair Cream, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Remedy Skin Repair Cream:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Mild itching, burning, or stinging.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); severe or persistent itching, burning, or stinging; skin irritation; worsening dryness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Remedy Skin Repair side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Remedy Skin Repair Cream:

Store Remedy Skin Repair Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not freeze. Keep Remedy Skin Repair Cream out of the reach of children and away from pets.


General information:


  • If you have any questions about Remedy Skin Repair Cream, please talk with your doctor, pharmacist, or other health care provider.

  • Remedy Skin Repair Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Remedy Skin Repair Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Remedy Skin Repair resources


  • Remedy Skin Repair Side Effects (in more detail)
  • Remedy Skin Repair Use in Pregnancy & Breastfeeding
  • Remedy Skin Repair Support Group
  • 0 Reviews for Remedy Skin Repair - Add your own review/rating


Compare Remedy Skin Repair with other medications


  • Dry Skin

Rescon JR





Dosage Form: tablet, multilayer, extended release
RESCON-Jr.®

DESCRIPTION


Nasal Decongestant / Antihistamine, sustained-release tablets for oral administration.


Each RESCON-Jr.® tablet contains:


Phenylephrine Hydrochloride               20 mg


Dexchlorpheniramine Maleate                3 mg


Phenylephrine HCI is a sympathomimetic amine with the chemical structure: Benzenemethanol, 3- hydroxy-(- [(methylamino)methyl]- hydrochloride.


C9H13NO2 • HCI                   M.W. 203.67



Dexchlorpheniramine Maleate is an antihistamine with the chemical structure: (+)-2-[p-Chloro-(- [2-(dimethylamino) ethyl]benzyl] pyridine maleate (1:1)


C16H19CIN2 • C4H4O4             M.W. 390.86




INACTIVE INGREDIENTS


calcium phosphate dibasic, D&C Yellow #10, magnesium stearate (veg.), methylcellulose, povidone, and silicified microcrystalline cellulose.



CLINICAL PHARMACOLOGY


Phenylephrine Hydrochloride is a sympathomimetic amine, which acts directly on (-adrenergic receptors in the mucosa of the respiratory tract to produce vasoconstriction that increases peripheral resistance, resulting in an increase in both systolic and diastolic blood pressure. Accompanying the pressor response is a marked reflex bradycardia due to increased vagal activity. It produces vasoconstriction that lasts longer than that produced by ephedrine and epinephrine, and in therapeutic doses, produces little or no central nervous system (CNS) stimulation. Phenylephrine has reduced bioavailability from the gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.


Dexchlorpheniramine Maleate is the dextro-isomer of the racemic compound chlorpheniramine maleate. In vitro and in vivo assays of the antihistamine potencies of the optically active isomers of chlorpheniramine demonstrate that the predominant activity is in the dextro-isomer. The dextro-isomer is approximately two times more active than the racemic compound. Dexchlorpheniramine maleate competitively antagonizes most of the smooth muscle stimulating actions of histamine on the H1 receptors of the GI tract, uterus, large blood vessels, and bronchial muscle. It also antagonizes the action of histamine that results in increased capillary permeability and the formation of edema. Dexchlorpheniramine maleate is an alkylamine-type antihistamine. This group of antihistamines is among the most active histamine antagonists and are generally effective in relatively low doses. They thereby prevent, but do not reverse, responses mediated by histamine alone. The anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. These drugs are not so prone to produce drowsiness and are among the most suitable agents for daytime use, but a significant proportion of patients do experience this effect.



INDICATIONS AND USAGE


This product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while dexchlorpheniramine maleate decreases the symptoms of watering eyes, post-nasal drip, and sneezing.



CONTRAINDICATIONS


This product is contraindicated in women who are pregnant or nursing. This product is contraindicated in children under six years of age because this age group is sensitive to the effects of sympathomimetic amines. It is also contraindicated in newborn or premature infants because this age group has an increased susceptibility to the anticholinergic side effects of dexchlorpheniramine maleate. Geriatric patients may be more sensitive to the effects of this medication. Risk-benefit should be considered when the following conditions exist:


Sensitivity to phenylephrine or dexchlorpheniramine; Acute asthma; Bladder neck obstruction; Brain damage in children; Cardiac disease, especially cardiac arrhythmias, congestive heart failure, coronary artery disease, and mitralstenosis; Cardiovascular disease; Diabetes mellitus; Down’s Syndrome; Esophagitis, reflux; Glaucoma; Acute hemorrhage with unstable cardiovascular status; Hepatic function impairment; Hernia; Hypertension; Hyperthyroidism; Intestinal atony in the elderly or debilitated patient; Chronic lung disease; Myasthenia gravis; Autonomic neuropathy; Paralytic ileus; Prostatic hypertrophy; Psychiatric disorders; Pyloric obstruction; Renal function impairment; Spastic paralysis, in children; Tachycardia; Toxemia of pregnancy; Ulcerative colitis; Urinary retention, or predisposition to; Uropathy; Xerostomia.



WARNINGS


This product may cause drowsiness or blurred vision. Patients taking this product should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous tasks while taking this drug. Sympathomimetic amines should be used with caution in patients with hypertension, ischemic heart disease, diabetes mellitus, increased intraocular pressure, hyperthyroidism, or prostatic hypertrophy. Sympathomimetic amines in overdosage may produce CNS stimulation with convulsions or cardiovascular collapse with accompanying hypotension. Do not exceed recommended dosage. Antihistamines should be used with considerable caution in pyloroduodenal obstruction; symptomatic prostatic hypertrophy; bladder neck obstruction. Antihistamines may cause excitability, especially in children. At dosages higher than the recommended dose, nervousness, dizziness or sleeplessness may occur. Do not exceed recommended dosage.



PRECAUTIONS



General


Use phenylephrine with caution in patients with hypoxia, acidosis, or a history of arteriosclerosis, bradycardia, partial heart block, hypertension, myocardial disease, thrombosis, or ventricular tachycardia. Antihistamines have an atropine-like action and should be used with caution in patients with a history of bronchial asthma, emphysema, increased intraocular pressure, hyperthyroidism, cardiovascular disease and hypertension.



Information for Patients


Patient consultation should include the following information regarding proper use of this medication:


•

Do not take more medication than the amount recommended.

•

May be taken with or without food; can be taken with food, a glass of water or milk to lessen stomach irritation if necessary.

•

Do not drive or operate machinery if drowsiness or dizziness occurs.

•

Do not ingest alcoholic beverages, monoamine oxidase (MAO) inhibitors, or CNS depression producing medications (hypnotics, sedatives, tranquilizers) while taking this medication.

•

This medication possibly increases sensitivity of eyes to light.

•

If a dose is missed, the medication should be taken as soon as possible unless it is almost time for the next dose: not doubling doses.

•

This medication should be stored in a tight, light-resistant container at temperatures between 20°- 25°C (68°-77°F), see USP Controlled Room Temperature. Avoid exposure to heat.

•

Keep all medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a poison control center immediately.

Caution patients about the signs of potential side effects, especially:


∙

Anticholinergic effects – clumsiness or unsteadiness; severe drowsiness; severe dryness of mouth, nose, or throat; flushing or redness of face; shortness of breath or troubled breathing.

∙

Blood dyscrasias - sore throat and fever; unusual bleeding or bruising; unusual tiredness or weakness.

∙

Fast or irregular heartbeat.

∙

Psychotic episodes.

∙

Tightness in chest.


Laboratory Tests


The following may be especially important in patient monitoring (other tests may be warranted in some patients, depending on conditions): Blood pressure determination– recommended at frequent intervals during therapy; Electrocardiogram (ECG) – monitoring may be required; Intraocular pressure determination - recommended at periodic intervals, as these medications may increase the intraocular pressure.



Drug Interactions


Do not take this product if you are presently taking, or have taken within the preceding two weeks, a prescription drug for high blood pressure without first consulting your physician. Combinations containing any of the following medications, depending on the amount present, may also interact with this product:


∙

(-adrenergic blocking agents or other medications with (-adrenergic blocking action -prior administration of (-adrenergics may block the pressor response to phenylephrine, possibly resulting in severe hypotension; medications with (-adrenergic blocking action may decrease the pressor effect and shorten the duration of action of phenylephrine.

∙

Anesthetics, hydrocarbon inhalation- Concurrent use of chloroform, cyclopropane, halothane, or trichloroethylene with phenylephrine may increase the risk of severe ventricular arrhythmias because these anesthetics greatly sensitize the myocardium to the effects of sympathomimetic amines; phenylephrine should be used with caution and in substantially reduced dosage in patients receiving these anesthetics. Enflurane, isoflurane, or methoxyflurane may also cause some sensitization of the myocardium to the effects of sympathomimetic amines.

∙

Anesthetics, parenteral-local - Phenylephrine should be used cautiously and in carefully circumscribed quantities, if at all, with local anesthetics for anesthetizing areas with end arteries (such as the fingers, toes, or penis) or otherwise compromised blood supply; ischemia leading to gangrene may result.

∙

Anticholinergics - Concurrent use with anticholinergics may intensify anticholinergic effects; patients should be advised to report occurrence of gastrointestinal problems promptly since paralytic ileus may occur with concurrent therapy.

∙

Antidepressants, tricyclic or maprotiline - Concurrent use may potentiate the cardiovascular effects of phenylephrine, possibly resulting in arrhythmias, tachycardia, or severe hypertension or hyperpyrexia.

∙

Antihypertensives, or diuretics used as - Antihypertensive effects may be reduced when these medications are used concurrently with phenylephrine; the patient should be carefully monitored to confirm that the desired effect is being obtained.

∙

(-adrenergic blocking agents - Therapeutic effects may be inhibited when these medications are used concurrently with phenylephrine, especially larger doses; also, (-adrenergic blockade may result in unopposed (-adrenergic activity with a risk of hypertension and excessive bradycardia with possible heart block.

∙

CNS Depressants – Concurrent use of antihistamines with alcohol, tricyclic antidepressants, barbiturates and other CNS depressants may have an additive effect.

∙

Cocaine, mucosal-local - Concurrent use with phenylephrine may increase the cardiovascular effects of either or both medications and the risk of adverse side effects.

∙

Digitalis glycosides – Concurrent use with phenylephrine may increase the risk of cardiac arrhythmias; caution and ECG monitoring are necessary if concurrent use is required.

∙

Ergoloid mesylates or Ergotamine - Concurrent ergoloid mesylates or ergotamine with phenylephrine may produce peripheral vascular ischemia and gangrene and is not recommended. Concurrent use of ergotamine with phenylephrine may potentiate the pressor effect of phenylephrine, resulting in possible severe hypertension and rupture of cerebral blood vessels.

∙

Doxapram - Concurrent use may increase the pressor effects of either doxapram or phenylephrine.

∙

Ketoconazole – Anticholinergics may increase gastrointestinal pH, possibly resulting in a marked reduction in ketoconazole absorption during concurrent use with anticholinergics; patients should be advised to take these medications at least 2hours after ketoconazole.

∙

Methyldopa - In addition to possibly decreasing the hypotensive effects of these medications, concurrent use may enhance the pressor response to phenylephrine; caution is required with very small initial doses of methyldopa being administered.

∙

MAO inhibitors – Concurrent use may prolong and intensify cardiac stimulant and vasopressor effects of phenylephrine and dexchlorpheniramine, resulting in headache, cardiac arrhythmias, vomiting or sudden and severe hypertensive and/or hyperpyretic crises. These medications should not be administered during or within 14 days following the administration of MAO inhibitor therapy.

∙

Potassium chloride – Concurrent use with anticholinergics may increase the severity of potassium chloride-induced gastrointestinal lesions.

∙

Rauwolfia alkaloids – Concurrent use may prolong the direct-acting sympathomimetic amines by preventing the uptake into storage granules.


DRUG & OR LABORATORY TEST INTERACTIONS


Antihistamines may interfere with diagnostic test results for skin tests using allergen extracts. Anticholinergics may interfere with diagnostic test results for gastric acid secretion by antagonizing the effect of pentagastrin and histamine, and for radio nucleotide gastric emptying studies by delaying gastric emptying.



Carcinogenesis, Mutagenesis, Impairment of Fertility


No data are available on the long term potential of the components of this product for carcinogenesis, mutagenesis or impairment of fertility in animals or humans.



Pregnancy


Pregnancy: Category C: Reproduction studies have been performed with chlorpheniramine maleate. Studies in rabbits and rats at doses up to 50 times and 85 times the human dose revealed no evidence of harm to the fetus. There are, however, no adequate and well controlled studies in pregnant women. Therefore, it is not known whether these drugs can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Animal reproduction studies have not been conducted with phenylephrine. This product should be given to a pregnant woman only if clearly needed.



Labor and Delivery


Use of phenylephrine during labor may cause fetal anoxia and bradycardia by increasing contractility of the uterus and decreasing uterine blood flow.



Nursing Mothers


Small amounts of sympathomimetic amines and antihistamines are excreted in breast milk; use is not recommended because of the risk of adverse effects, such as unusual excitement or irritability, in infants. Anticholinergics and antihistamines may inhibit lactation.



Pediatric Use


Use of antihistamines is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as CNS excitation, and an increased tendency toward convulsion. In infants and children, overdosage may cause hallucinations, convulsions, and death. A paradoxical reaction characterized by hyperexcitability may occur in older children taking antihistamines. Use is not recommended for children under six years of age. Appropriate studies with phenylephrine have not been performed in the pediatric population; however, no pediatric specific problems have been documented to date.



Geriatric Use


Confusion, hallucinations, seizures and CNS depression may be more likely to occur in geriatric patients taking sympathomimetic amines. Geriatric patients also may be more sensitive to the effects, especially the vasopressor effects, of sympathomimetic amines. Confusion, dizziness, sedation, hypotension, hyperexcitability, and anticholinergic side effects, such as dryness of mouth and urinary retention (especially in males), may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients may respond to usual doses of anticholinergics with excitement, agitation, drowsiness, or confusion. Geriatric patients are especially susceptible to the anticholinergic side effects, such as constipation, dryness of mouth, and urinary retention (especially in males). If these side effects occur and continue or are severe, medication should probably be discontinued. Caution is also recommended when anticholinergics are given to geriatric patients, because of the danger of precipitating undiagnosed glaucoma. Memory may become severely impaired in geriatric patients, especially those who already have memory problems, with the continued use of anticholinergics, since these drugs block the action of acetylcholine, which is responsible for many functions of the brain, including memory function.



ADVERSE REACTIONS


The following adverse reactions have been observed with the use of phenylephrine and dexchlorpheniramine: Arrhythmias, blood dyscrasias, CNS depression, CNS stimulation, dizziness, drowsiness, dryness of mouth, hallucinations, hypotension, hypertension, increased sensitivity of skin to sun, increased sweating, loss of appetite, paradoxical reaction, restlessness, skin rash, stomach upset or pain, thickening of mucus, tingling in hands or feet, trembling, troubled breathing, unusual tiredness or weakness, vomiting.


Note: Agitation; confusion; difficult or painful urination; drowsiness; dizziness; and dryness of mouth, nose or throat are more likely to occur in the elderly. Nightmares, unusual excitement, nervousness, restlessness, or irritability are more likely to occur in children and the elderly.



DRUG ABUSE AND DEPENDENCE


Central nervous system stimulants such as phenylephrine have been abused. At high doses, subjects commonly experience an elevation of mood, a sense of increased energy and alertness, and decreased appetite. Some individuals become anxious, irritable and loquacious. In addition to the marked euphoria, the user experiences a sense of markedly enhanced physical strength and mental capacity. With continued use, tolerance develops, the user increases the dose, and toxic signs and symptoms appear. Depression may follow rapid withdrawal. Stimulants, such as phenylephrine, are banned and tested for by the US Olympic Committee (USOC) and the National Collegiate Athletic Association (NCAA).



OVERDOSAGE


This product is comprised of pharmacologically different components (sympathomimetic amine, and antihistamine). Therefore, it is difficult to predict the exact manifestation of symptoms in a given individual. Reaction to an overdose of this product may vary from CNS depression to stimulation. A description of symptoms which are likely to appear after ingestion of an excess of the individual components follows:


∙

Overdosage with sympathomimetic amines can cause cardiac arrhythmias, cerebral hemorrhage and pulmonary edema. It can also cause palpitations, tremor, dizziness, vomiting, fear, labored breathing, headache, dryness of mouth, pallor, weakness, panic, anxiety, confusion, and hallucination.

∙

Manifestation of antihistamine overdosage may vary from CNS depression to stimulation. Other signs and symptoms may be dizziness, tinnitus, ataxia, blurred vision, and hypotension. Stimulation is particularly likely in children as are atropine-like signs and symptoms (dry mouth, fixed, dilated pupils, flushing, hyperthermia, and gastrointestinal symptoms). In infants and children particularly, antihistamines, in overdosage may produce convulsion and/or death.

Treatment of acute overdosage would probably be based upon treating the patient for phenylephrine toxicity which may manifest itself as excessive CNS stimulation resulting in excitement, tremor, restlessness, and insomnia. Other effects may include hyperpyrexia, hypertension, mydriasis, hyperglycemia and urinary retention. Severe overdosage may cause tachypnea or hyperpnea, convulsions or delirium, but in some individuals there may be CNS depression with somnolence, stupor, or respiratory depression. Arrhythmias may lead to hypotension and circulatory collapse. Severe hypokalemia can occur, probably due to a compartmental shift rather than a depletion of potassium. No organ damage or significant metabolic derangement is associated with overdosage.


General Treatment: Treatment is symptomatic and supportive with possible utilization of the following:


∙

Induction of emesis (syrup of Ipecac recommended); however, precaution against aspiration is necessary, especially in infants and children.

∙

Gastric lavage (isotonic or 0.45% sodium chloride solution) if patient is unable to vomit within three hours of ingestion.

∙

Saline cathartics (milk of magnesia) may be used.

∙

Vasopressors to treat hypotension; however, epinephrine should not be used since it may further lower blood pressure.

∙

For excessive hypertensive effect an (-adrenergic blocker, such as phentolamine, may be administered.

∙

Hyperpyrexia, especially in children, may require treatment by means of external cooling.

∙

Excessive CNS stimulation may be counteracted with parenteral diazepam.

∙

Oxygen and intravenous fluids.

∙

Precaution against the use of stimulants (analeptic agents) is recommended because they may cause seizures.

∙

Excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100 - 200 mL of a 2% solution) by rectal infusion. In severe cases of overdosage it is essential to monitor both the heart (by electrocardiograph) and plasma electrolytes, and to give intravenous potassium as indicated. In the event of progression of the curare-like effect to paralysis of the respiratory muscles or apnea, artificial respiration should be instituted and maintained until effective respiratory action returns.


DOSAGE AND ADMINISTRATION


Adults and adolescents 12 years of age and older: 1 or 2 tablets every 12 hours as directed by a physician.


Children 6 to 12 years of age: 1 tablet every 12 hours as directed by a physician.


Not recommended for children under 6 years of age. Do not crush or chew tablets prior to swallowing.


Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Adjust adult dose accordingly.



HOW SUPPLIED


Supplied as yellow & white, bilayered, capsule-shaped tablets debossed “RES JR” on one side and scored on the opposite. Available in bottles of 90 tablets, NDC 64543-084-90, and sample packs of 2 tablets, NDC 64543-084-02.


KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN. IN CASE OF ACCIDENTAL OVERDOSE, CALL A DOCTOR OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.



Storage and Handling


Dispense in tight, light resistant containers as defined in the USP/NF, with child resistant closures. Store at controlled room temperature between 20°- 25°C (68°- 77°F); see USP Controlled Room Temperature. Avoid exposure to heat.


Call Your Doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Manufactured for:

Capellon Pharmaceuticals, LLC

Fort Worth, TX 76118


Rev. 06/2009


500390



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL



Figure 1: 90 ct. Label



Figure 2: Blister label









Rescon JR 
phenylephrine hydrochloride / dexchlorpheniramine maleate  tablet, multilayer, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)64543-084
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PHENYLEPHRINE HYDROCHLORIDE (PHENYLEPHRINE)PHENYLEPHRINE HYDROCHLORIDE20 mg
DEXCHLORPHENIRAMINE MALEATE (DEXCHLORPHENIRAMINE)DEXCHLORPHENIRAMINE MALEATE3 mg


















Inactive Ingredients
Ingredient NameStrength
DIBASIC CALCIUM PHOSPHATE DIHYDRATE 
D&C YELLOW NO. 10 
MAGNESIUM STEARATE 
HYPROMELLOSE 2208 (4000 MPA.S) 
POVIDONE K30 
CELLULOSE, MICROCRYSTALLINE 
SILICON DIOXIDE 


















Product Characteristics
ColorYELLOW, WHITEScore2 pieces
ShapeCAPSULESize15mm
FlavorImprint CodeRES;JR
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
164543-084-9090 TABLET In 1 BOTTLENone
264543-084-022 TABLET In 1 BLISTER PACKNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/21/201004/30/2012


Labeler - Capellon Pharmaceuticals, LLC (124568093)

Registrant - Capellon Pharmaceuticals, LLC (124568093)









Establishment
NameAddressID/FEIOperations
Sovereign Pharmaceuticals, LLC623168267MANUFACTURE
Revised: 01/2010Capellon Pharmaceuticals, LLC

repaglinide


re-PAG-li-nide


Commonly used brand name(s)

In the U.S.


  • Prandin

Available Dosage Forms:


  • Tablet

Therapeutic Class: Hypoglycemic


Chemical Class: Meglitinide


Uses For repaglinide


Repaglinide is used to treat type 2 diabetes. When you have type 2 diabetes, insulin is still being produced by your pancreas. Sometimes the amount of insulin you produce may not be enough or your body may not be using it properly and you may still need more. Repaglinide works by causing your pancreas to release more insulin into the blood stream. Repaglinide may be used alone or with another oral diabetes medicine called metformin.


repaglinide is available only with your doctor's prescription.


Before Using repaglinide


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For repaglinide, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to repaglinide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Studies on repaglinide have been done only in adult patients, and there is no specific information comparing use of repaglinide in children with use in other age groups.


Geriatric


repaglinide has been tested in a limited number of patients 65 years of age or older and has not been shown to cause different side effects or problems in older people than it does in younger adults. However, the first signs of low blood sugar are not easily seen or do not occur at all in older patients. This may increase the chance of low blood sugar developing during treatment.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking repaglinide, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using repaglinide with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Gemfibrozil

Using repaglinide with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Itraconazole

Using repaglinide with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Acebutolol

  • Alprenolol

  • Atenolol

  • Betaxolol

  • Bevantolol

  • Bisoprolol

  • Bitter Melon

  • Bucindolol

  • Carteolol

  • Carvedilol

  • Celiprolol

  • Clarithromycin

  • Clorgyline

  • Cyclosporine

  • Deferasirox

  • Dilevalol

  • Eltrombopag

  • Esmolol

  • Fenugreek

  • Glucomannan

  • Guar Gum

  • Iproniazid

  • Isocarboxazid

  • Ketoconazole

  • Labetalol

  • Levobunolol

  • Mepindolol

  • Metipranolol

  • Metoprolol

  • Moclobemide

  • Nadolol

  • Nebivolol

  • Nialamide

  • Oxprenolol

  • Pargyline

  • Penbutolol

  • Phenelzine

  • Pindolol

  • Procarbazine

  • Propranolol

  • Psyllium

  • Rifampin

  • Rifapentine

  • Selegiline

  • Sotalol

  • Talinolol

  • Telithromycin

  • Tertatolol

  • Timolol

  • Toloxatone

  • Tranylcypromine

  • Trimethoprim

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Other Medical Problems


The presence of other medical problems may affect the use of repaglinide. Make sure you tell your doctor if you have any other medical problems, especially:


  • Infection or

  • Ketones in the blood (diabetic ketoacidosis) or

  • Surgery or

  • Trauma or

  • Type 1 (insulin-dependent) diabetes or

  • Unusual stress—Insulin may be needed to control diabetes in patients with these conditions

  • Kidney disease or

  • Liver disease—Higher blood levels of repaglinide may occur; this may change the amount of medicine you need

  • Underactive adrenal gland or

  • Underactive pituitary gland or

  • Undernourished condition or

  • Weakened physical condition—Patients with these conditions may be more likely to develop low blood sugar while taking repaglinide

Proper Use of repaglinide


Follow carefully the special meal plan your doctor gave you. This is the most important part of controlling your condition, and is necessary if the medicine is to work properly. Also, exercise regularly and test for sugar in your blood or urine as directed.


repaglinide usually is taken 15 minutes before a meal but may be taken up to 30 minutes before a meal.


Dosing


The dose of repaglinide will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of repaglinide. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage form (tablets):
    • For type 2 diabetes:
      • Adults:
        • For patients who have never taken medicine to lower their blood sugar or who have a glycosylated hemoglobin (hemoglobin A 1c) measurement that is less than 8%: At first the dose is 0.5 milligram (mg) fifteen to thirty minutes before each meal. The dose may then be adjusted by your doctor based on your fasting blood sugar level.

        • For patients who have taken medicine to lower their blood sugar and who have a hemoglobin A 1c measurement that is higher than 8%: At first the dose is 1 or 2 mg fifteen to thirty minutes before each meal. The dose may then be adjusted by your doctor based on your fasting blood sugar level.


      • Children: Use and dose must be determined by your doctor.



Missed Dose


Call your doctor or pharmacist for instructions.


You should skip a dose of repaglinide if a meal is skipped and add a dose of repaglinide if you eat an extra meal.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using repaglinide


Your doctor will want to check your progress at regular visits , especially during the first few weeks you take repaglinide.


It is very important to follow carefully any instructions from your health care team about:


  • Alcohol—Drinking alcohol may cause severe low blood sugar. Discuss this with your health care team.

  • Other medicines—Do not take other medicines during the time you are taking repaglinide unless they have been discussed with your doctor. This especially includes nonprescription medicines such as aspirin, and medicines for appetite control, asthma, colds, cough, hay fever, or sinus problems.

  • Counseling—Other family members need to learn how to prevent side effects or help with side effects if they occur. Also, patients with diabetes may need special counseling about diabetes medicine dosing changes that might occur because of lifestyle changes, such as changes in exercise and diet. Furthermore, counseling on contraception and pregnancy may be needed because of the problems that can occur in patients with diabetes during pregnancy.

  • Travel—Keep a recent prescription and your medical history with you. Be prepared for an emergency as you would normally. Make allowances for changing time zones and keep your meal times as close as possible to your usual meal times.

In case of emergency—There may be a time when you need emergency help for a problem caused by your diabetes. You need to be prepared for these emergencies. It is a good idea to wear a medical identification (ID) bracelet or neck chain at all times. Also, carry an ID card in your wallet or purse that says that you have diabetes and a list of all of your medicines.


Too much repaglinide can cause low blood sugar (hypoglycemia). Low blood sugar also can occur if you use repaglinide with another antidiabetic medicine, delay or miss a meal or snack, exercise more than usual, drink alcohol, or cannot eat because of nausea or vomiting. Symptoms of low blood sugar must be treated before they lead to unconsciousness (passing out). Different people may feel different symptoms of low blood sugar. It is important that you learn which symptoms of low blood sugar you usually have so that you can treat it quickly.


Symptoms of low blood sugar include anxiety; behavior change similar to being drunk; blurred vision; cold sweats; confusion; cool, pale skin; difficulty in thinking; drowsiness; excessive hunger; fast heartbeat; headache (continuing); nausea; nervousness; nightmares; restless sleep; shakiness; slurred speech; or unusual tiredness or weakness.


If symptoms of low blood sugar occur, eat glucose tablets or gel, corn syrup, honey, or sugar cubes; or drink fruit juice, nondiet soft drink, or sugar dissolved in water to relieve the symptoms. Also, check your blood for low blood sugar. Get to a doctor or a hospital right away if the symptoms do not improve. Someone should call for emergency help immediately if severe symptoms such as convulsions (seizures) or unconsciousness occur. Food or drink should not be forced because the patient could choke from not swallowing correctly.


Hyperglycemia (high blood sugar) may occur if you do not take enough or skip a dose of your antidiabetic medicine, overeat or do not follow your meal plan, have a fever or infection, or do not exercise as much as usual.


Symptoms of high blood sugar include blurred vision; drowsiness; dry mouth; flushed, dry skin; fruit-like breath odor; increased urination; ketones in urine; loss of appetite; stomachache, nausea, or vomiting; tiredness; troubled breathing (rapid and deep); unconsciousness; or unusual thirst.


If symptoms of high blood sugar occur, check your blood sugar level and then call your doctor for instructions.


repaglinide Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Convulsions (seizures)

  • unconsciousness

Check with your doctor as soon as possible if any of the following side effects occur:


More common
  • Cough

  • fever

  • low blood sugar, including anxious feeling, behavior change similar to being drunk, blurred vision, cold sweats, confusion, cool pale skin, difficulty in thinking, drowsiness, excessive hunger, fast heartbeat, headache, nausea, nervousness, nightmares, restless sleep, shakiness, slurred speech, or unusual tiredness or weakness

  • pain in the chest

  • runny or stuffy nose

  • shortness of breath

  • sinus congestion with pain

  • sneezing

  • sore throat

Less common
  • Bloody or cloudy urine

  • burning, painful, or difficult urination

  • chest pain

  • chills

  • frequent urge to urinate

  • problems with teeth

  • skin rash, itching, or hives

  • tearing of eyes

  • tightness in chest

  • trouble in breathing

  • vomiting

  • wheezing

Rare
  • Black, tarry stools

  • blood in stools

  • fast or irregular heartbeat

  • hoarseness

  • lower back or side pain

  • pinpoint red spots on skin

  • unusual bleeding or bruising

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Back pain

  • diarrhea

  • joint pain

Less common
  • Constipation

  • feeling of burning, numbness, tightness, tingling, warmth, or heat

  • indigestion

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: repaglinide side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More repaglinide resources


  • Repaglinide Side Effects (in more detail)
  • Repaglinide Dosage
  • Repaglinide Use in Pregnancy & Breastfeeding
  • Repaglinide Drug Interactions
  • Repaglinide Support Group
  • 5 Reviews for Repaglinide - Add your own review/rating


  • Repaglinide Professional Patient Advice (Wolters Kluwer)

  • Repaglinide Monograph (AHFS DI)

  • Repaglinide MedFacts Consumer Leaflet (Wolters Kluwer)

  • Prandin Prescribing Information (FDA)

  • Prandin Consumer Overview



Compare repaglinide with other medications


  • Diabetes, Type 2